“showed a trend”

A comparison of Receptor-ITH between Grades 2 and 3 showed a trend toward reduced ITH with cancer progression ( p = 0.12; Fig. 2E , Supplementary Data 3 ).

No notable differences were observed, but BMI in males showed a trend of increasing with age (p=0.12).

The current density of p.I1498M showed a 59% reduction, whereas the other variants did not show statistically significant modifications (although p.R1636Q showed a trend towards reduction, P = 0.12).

In contrast, in primary PCa, the Wnt pathway showed a trend towards increased activity (p = 0.12), and median FOXO activity was only slightly lower than in healthy tissue (p = 0.12) indicating that PI3K pathway activity was restricted to a subgroup of PCa.

After propensity‐score adjustment, PF‐AES showed a trend toward a lower rate of MACCE and a favorable rate of TLF as compared to PP‐ZES (HR 0.70; 95%CI 0.45 to 1.10, P = 0.12; and HR 0.88; 95%CI 0.47 to 1.65, P = 0.68, respectively).

The lobular carcinomas in the present series all fell into the grade 2 category and also showed a trend for increase of expression (chi-squared test P = 0.12; Table 2 ) of NR4A1 compared with grade 3 primary infiltrating ductal carcinomas.

For protons, 200 cGy caused a −22% decrement in BV/TV ( Figure 3 A) and Tb.N ( Figure 3 B), while 50 cGy showed a trend towards decreased BV/TV (−11%, p = 0.12) and Tb.N (−13%, p = 0.06).

Time spent doing reconstructive surgery did not statistically significantly influence overall breast aesthetic score but showed a trend toward higher scoring ( P = 0.12).

Analysis of dependency of BIS-reduction on daytime showed a trend for HGSHS-5 (BIS total intervention) with 88.8 at noon vs. 90.5 in the morning and evening ( p = 0.12).

Results: The median OS showed a trend towards longer survival in the dose-escalated arm (11.8 vs 9.6 months; hazard ratio (HR), 0.75; one-sided P =0.12), although it was statistically not significant.

The IS1 group showed a trend of decreased overall survival possibilities ( p = 0.12), and a larger sample size is needed to determine whether immunotypes could serve as a robust prognostic indicator for PRCC.

On WATER DAY, glucose concentration did not change at any moment, except for the FG on FATIGUE, which showed a trend to a higher glucose concentration compared to rest (WATER DAY–97.2 ± 16.72 mg/dl FG REST; 118 ± 39.1 mg/dl FG FATIGUE p = 0.12) this glucose increase happened due to the high intensity of the fatigue protocol and the consequent hormonal responses to the stress stimulus, as promoted by the HPA axis activation [ 18 ].

Surface SERT binding showed a trend toward a decrease in maximal binding in ‘ S ' allele carriers ( Figure 3b ; P <0.12).

reported significantly elevated post-exercise noradrenaline levels in the BFR group compared to controls ( p < 0.05), while growth hormone showed a trend toward elevation that did not reach statistical significance ( p = 0.12) [ 33 ].

Interim OS data showed a trend towards benefit for both combination arms compared to CP alone (P=0.12 with CP + durvalumab versus CP; HR, 0.77; P=0.003 with CP + durvalumab + olaparib vs.

Differences between groups were observed, as MSCs from COPD patients secreted significantly higher amounts of IL-6 and showed a trend towards higher IL-8 secretion (p=0.12) ( figure 3b ).

Similarly, interventions using either probiotics or FMT were associated with an increased ORR (pooled OR = 1.62, P = 0.006) and showed a trend toward improved DCR (pooled OR = 1.74, P = 0.12).

Although survival differences among infiltration groups did not reach statistical significance, T-cell infiltrated patients showed a trend toward improved outcomes ( online supplemental figure 2B ; HR=0.31, p=0.12).

In the Fine-Gray model, presence of AKI at the landmark timepoint showed a trend towards positive with an HR of 1.09 without reaching significance thresholds (CI 0.98–1.21, p = 0.12).

Pre-transplant and posttransplant MAGE-C1/CT7 concentrations (C-statistic = 0.75 [0.65, 0.85]) showed a trend toward being a more accurate predictor of PFS compared to MPFC data (C-statistic = 0.65 [0.55, 0.75], p = 0.12).

Both indices of HIC showed a trend of an association with increased risk of metabolic syndrome (HIC C-peptide odds ratio 1.13 [95% CI 0.97–1.31], P = 0.12, and HIC ISR 1.38 [0.88–2.17], P = 0.16) and impaired glucose metabolism (HIC C-peptide 1.12 [0.92–1.36], P = 0.26, and HIC ISR 1.31 [0.74–2.33] P = 0.36), although point estimates reached no statistical significance.

When later events were included, both the REMoDL-B and LLMPP data showed similar results (OS HR = 2.11, 95% CI = 1.115–3.993; p = .019 and HR = 2.17, 95% CI = 1.109–4.242; p = .02; supplemental Figure 3 A,B, respectively), while the HMRN cohort showed a trend for reduced survival in the high-risk group, (HR = 1.39, 95% CI = 0.917–2.106; p = .12; supplemental Figure 3 C); and we have reasoned that the performance of the discriminator may reflect the number of non-lymphoma–related deaths in this population-based cohort.

JAK1-selective inhibitor showed a trend for better retention rate compared to pan-JAK inhibitors ( p = 0.12; Figure 3 ).

Although four randomized phase III trials that evaluated the efficacy of concurrent erlotinib or gefitinib administration with standard platinum-doublet chemotherapy failed to show evidence of improved survival [ 11 - 14 ], the phase II First-Line Asian Sequential Tarceva and Chemotherapy Trial (FAST-ACT) proved that the sequential administration of TKI following chemotherapy led to a significant improvement in progression-free survival (PFS; P = 0.0002) and patients showed a trend toward a better tumor response rate (35.5% versus 24.4%; P = 0.12) [ 15 ].

This effect was not observed with high-dose vaccine, where Pfs25 showed a trend to lower antibody levels after coadministration of the 2 vaccines ( Figure 2G compared with Figure 2B, P = 0.12), and there was no effect of vaccine combinations on anti-Pfs230 responses ( Figure 2, H and I ).